Autolus Therapeutics plc (NASDAQ: AUTL) has had a notable surge in its stock price on the US stock charts after the FDA has cleared its
Autolus Therapeutics plc (NASDAQ: AUTL) is down by nearly 60% in the last 12 months. It dabbles in a highly sensitive area, of cancer research,
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.